Text Size
7 studies found for:    EXT2

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting A Study of V503 in Preadolescents and Adolescents (V503-002 EXT1 EXT2)
Conditions: Cervical Cancers;   Vulvar Cancer;   Vaginal Cancer;   Genital Lesions;   PAP Test Abnormalities;   HPV Infections
Intervention: Biological: V503
2 Active, not recruiting
Has Results 		Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015 AM5; EXT1; EXT2(AM1))
Conditions: Cervical Cancer;   Genital Warts
Interventions: Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine;   Biological: Matching Placebo
3 Completed
Has Results 		A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019 EXT2)
Condition: HIV Infections
Interventions: Drug: raltegravir potassium;   Drug: Comparator: placebo
4 Completed
Has Results 		A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
Condition: HIV Infections
Interventions: Drug: raltegravir potassium;   Drug: Comparator: Placebo
5 Active, not recruiting
Has Results 		A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019 AM4, EXT1, EXT2 [AM1])
Conditions: Healthy;   Papillomavirus Infection
Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine;   Biological: Comparator: Placebo
6 Active, not recruiting
Has Results 		An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020 AM4, EXT1, EXT2 [AM1])
Condition: Condylomata Acuminata
Interventions: Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Biological: Comparator: placebo (unspecified)
7 Terminated Three Cycle Extension Study Evaluating Safety and Efficacy of a 25 mg Daily Dose of Proellex® In Pre-Menopausal Women With Leiomyomata Who Have Previously Completed ZPU 003 Ext
Condition: Uterine Fibroids
Intervention: Drug: Proellex®
To Top

† Indicates status has not been verified in more than two years